A U.S. court has charged Sanjay Kumar, a 43-year-old Indian national from Bihar, with selling and distributing counterfeit oncology pharmaceuticals in the United States. The charges, announced on Thursday, accuse Kumar and his accomplices of orchestrating the sale and shipment of fraudulent versions of critical cancer medications, including Keytruda, to individuals within the U.S.
Keytruda is a widely used cancer immunotherapy drug that is approved for treating various cancers such as melanoma, lung cancer, head and neck cancer, Hodgkin lymphoma, gastric cancer, cervical cancer, and breast cancer. It is exclusively manufactured and marketed by Merck Sharp & Dohme LLC, formerly known as Merck Sharp & Dohme Corp., which holds the sole rights to authorize its manufacture and distribution.
According to court documents, Kumar was arrested on June 26 in Houston. He had traveled to the U.S. to further his illicit business of selling counterfeit Keytruda. The case reveals that Kumar’s operations involved sophisticated schemes to smuggle fake pharmaceuticals into the U.S. market, undermining the integrity of cancer treatments and potentially endangering patients’ lives.
Kumar faces serious charges including one count of conspiracy to traffic in counterfeit drugs and four counts of trafficking in counterfeit drugs. If convicted, he could face a maximum of 20 years in prison on each count. The case underscores the ongoing challenges in combating the global trade in counterfeit medicines and highlights the critical need for stringent enforcement to protect public health.
The authorities’ swift action aims to prevent further distribution of counterfeit drugs and to ensure accountability for those who compromise the safety and efficacy of essential medications.
